Drug Induced Liver Disease Study Group
6
1
2
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
17%
1 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）
Role: lead
A Retrospective Study in Patients With Liver Injury After the Use of Novel Antineoplastic Agents
Role: lead
The Multi-Center, Randomized, Double-blind, Positive Controlled Clinical Trial of Bicyclol in the Treatment of Acute DILI
Role: lead
A Diagnostic Study on Patients With Drug-induced Liver Injury
Role: lead
The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI
Role: lead
A Retrospective Study on Drug Induced Liver Injury in China
Role: lead
All 6 trials loaded